Vonoprazan

• CAT Number: I010041
• CAS Number: 881681-00-1
• Molecular Formula: C17H16FN3O2S
• Molecular Weight: 345.39
• Purity: ≥95%
• Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
• Target: K+-ATPase
• Target Protein: P51164
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50: 19 nM
• InChI: InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
• InChIKey: BFDBKMOZYNOTPK-UHFFFAOYSA-N
• SMILES: CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3

Vonoprazan（Cat No.:I010041）is a novel potassium-competitive acid blocker (P-CAB) used to treat acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Unlike traditional proton pump inhibitors (PPIs), Vonoprazan works by reversibly blocking the H+/K+-ATPase enzyme in the stomach, providing faster and longer-lasting acid suppression. Its rapid onset and potent acid inhibition make it highly effective for managing conditions requiring reduced gastric acid production. Vonoprazan offers a well-tolerated alternative to PPIs, improving symptom control and healing in patients with GERD, ulcers, and Helicobacter pylori infections.

Reference

[1]. Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456.
[Content Brief]

[2]. Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238.
[Content Brief]

[3]. Sugimoto M, et al. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019 Jan 15;9:1560.
[Content Brief]